Emerging biomarkers, tools, and treatments for diabetic polyneuropathy.

Emerging biomarkers, tools, and treatments for diabetic polyneuropathy. Endocr Rev. 2018 Sep 25;: Authors: Bönhof GJ, Herder C, Strom A, Papanas N, Roden M, Ziegler D Abstract Diabetic neuropathy, with its major clinical sequels notably neuropathic pain, foot ulcers, and autonomic dysfunction, is associated with substantial morbidity, increased risk of mortality, and reduced quality of life. Despite its major clinical impact, diabetic neuropathy remains underdiagnosed and undertreated. Moreover, the evidence supporting a benefit for causal treatment is weak at least in patients with type 2 diabetes, and current pharmacotherapy is largely limited to symptomatic treatment options. Thus, a better understanding of the underlying pathophysiology is mandatory for translation into new diagnostic and treatment approaches. Improved knowledge about pathogenic pathways implicated in the development of diabetic neuropathy could lead to novel diagnostic techniques that have the potential of improving the early detection of neuropathy in diabetes and prediabetes to eventually embark on new treatment strategies. Here we first provide an overview on the current clinical aspects and illustrate the pathogenetic concepts of (pre)diabetic neuropathy. We then describe the biomarkers emerging from these concepts and novel diagnostic tools and appraise their utility in the early detection and prediction of predominantly distal sensorimotor polyneuropathy ...
Source: Endocrine Reviews - Category: Endocrinology Tags: Endocr Rev Source Type: research